Comparative Pharmacology
Head-to-head clinical analysis: DIONOSIL OILY versus IOHEXOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIONOSIL OILY versus IOHEXOL.
DIONOSIL OILY vs IOHEXOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DIONOSIL OILY is a radiographic contrast agent containing propyliodone, which is an iodine-containing compound that absorbs X-rays, thereby enhancing the visualization of body structures during imaging procedures.
Non-ionic, water-soluble, iodinated contrast agent that increases the radiopacity of vascular structures and body cavities, allowing visualization during radiographic procedures. It does not bind to serum proteins and is rapidly distributed in extracellular fluid.
Adults: 10 mL intraurethral instillation as a sterile oily suspension (50% w/v) once daily for 3-5 days.
Intravenous: 300-370 mg iodine/kg (0.3-0.37 mL/kg of 300 mg I/mL solution) for contrast imaging; typical range 15-150 mL per procedure depending on examination. Intra-arterial: Doses vary by procedure, typically 1-10 mL total. Do not exceed 3 mL/kg total dose.
None Documented
None Documented
Clinical Note
moderateIohexol + Metformin
"The risk or severity of adverse effects can be increased when Iohexol is combined with Metformin."
Terminal elimination half-life of the iodine moiety is approximately 60 days due to slow release from fatty tissues. This long half-life reflects the persistence of the oily vehicle and slow deiodination, necessitating monitoring for cumulative iodine effects.
Terminal elimination half-life approximately 2-3 hours in patients with normal renal function. In patients with severe renal impairment (CrCl <30 mL/min), half-life may be prolonged up to 30-60 hours, necessitating dose adjustment or avoidance.
Primarily renal excretion of the water-soluble metabolite (propiodone) after hepatic deiodination; approximately 60-80% of the administered iodine is excreted in urine within 48 hours. Fecal excretion is negligible (<5%).
Primarily renal via glomerular filtration; 90-100% of administered dose excreted unchanged in urine within 24 hours. Less than 2% excreted in feces. Biliary excretion negligible (<1%).
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent